University of Pennsylvania - Articles and news items

Novartis’ lymphoma treatment receives FDA breakthrough therapy designation

Industry news / 19 April 2017 / Niamh Marriott, Junior Editor

The US Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to Novartis’ CTL019, an investigational chimeric antigen receptor T cell (CAR-T) therapy, for the treatment of adult patients with relapsed and refractory (r/r) diffuse large B-cell lymphoma (DLBCL), who have failed two or more prior therapies. This is the second indication for which […]

Mutations in CLL suggest potential new uses for existing cancer drugs

Industry news / 7 December 2015 / Victoria White

By mining the DNA of patients with chronic lymphocytic leukaemia (CLL), researchers at Penn Medicine have uncovered 12 mutations that may be targetable using therapies already available for other cancers…

Figure 5: VHP can stratify CVD status. The profile computationally combines EPC and MP measures. In the upper panel, the vertical axis represents a measure of a subpopulation of endothelial microparticles and the horizontal axis a measure of EPCs

High dimensional flow cytometry comes of age

Flow Cytometry, Issue 4 2012 / 3 September 2012 / Jonni Moore, Professor of Pathology and Laboratory Medicine, Director, Clinical Flow Cytometry, Hospital of University of Pennsylvania, Director, Abramson Cancer Center Flow Cytometry and Cell Sorting Shared Resource – Perelman School of Medicine of the University of Pennsylvania and Pascal Yvon, CEO, CytoVas

Technologies for single cell analysis have recently become prominent in the emerging life science sectors. The last few decades have seen an explosion in advancements in cytometric technologies encompassing instrumentation, probes and data analysis. In particular, flow cytometry has become a well-established and routine method in clinical laboratories. Recent developments have placed high dimensional flow cytometry at the forefront of new applications critical for the pharmaceutical sector and clinical laboratories. The integration of systems biology concepts into biomedical studies has resulted in trans – formative advancements in both the amount and type of information that can be gained to help understand the basis of biocomplexity in health and disease. All aspects of a biological process from biochemical, genetic and cellular to clinical and environmental can be integrated using computational models to derive unique signatures from vast amounts of data. The changes in these signatures, often unique to the individual, can serve to define patho – physiological conditions…

Novartis logo


The deadline for submissions to the EPR Awards is 9 June 2017! Entry is FREE, so don't delay...